Journal Mobile Options
Table of Contents
Vol. 172, No. 3, 2002
Issue release date: 2002
Section title: Paper
Cells Tissues Organs 2002;172:161–173
(DOI:10.1159/000066968)

Leukocyte Adhesion Deficiency II: Therapy and Genetic Defect

Wild M.K. · Lühn K. · Marquardt T. · Vestweber D.
aInstitut für Zellbiologie, Zentrum für Molekularbiologie der Entzündung, bKlinik und Poliklinik für Kinderheilkunde, Universität Münster, cMax-Planck-Institut für Vaskuläre Biologie, Münster, Germany

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Paper

Received: 12/17/2001
Published online: 12/18/2002

Number of Print Pages: 13
Number of Figures: 10
Number of Tables: 1

ISSN: 1422-6405 (Print)
eISSN: 1422-6421 (Online)

For additional information: http://www.karger.com/CTO

Abstract

Leukocyte adhesion deficiency II (LAD II) is a rare congenital disease which is caused by a defect in fucosylation of glycoconjugates. Hypofucosylated structures include ligands for the selectin family of adhesion molecules. This results in a leukocyte adhesion defect causing an immunodeficiency. In addition, LAD II patients show severe mental and growth retardations suggesting a role of fucose in development. Recently, a LAD II patient was treated with oral supplementation of fucose. This simple therapy restored selectin ligands and corrected the immunodeficiency. However, in another patient the treatment protocol had no effect indicating that the biochemical defect in the latter patient is somewhat different. The genetic defect in LAD II has now been located to a gene encoding a GDP-fucose transporter which gates GDP-fucose into the Golgi where fucose is transferred onto glycoconjugates. Point mutations have been detected in this gene in several LAD II patients, which inactivate the transporter function. Thus, LAD II represents the first developmental and immune defect that is based on a malfunctioning nucleotide sugar transporter.


  

Author Contacts

Martin K. Wild
Institut für Zellbiologie, ZMBE, Universität Münster
Von-Esmarch-Strasse 56
D–48149 Münster (Germany)
Tel. +49 251 83 58 613, Fax +49 251 83 52 236, E-Mail wildm@uni-muenster.de

  

Article Information

Number of Figures : 10, Number of Tables : 1, Number of References : 47

  

Publication Details

Cells Tissues Organs (in vivo, in vitro)
Founded 1945 as Acta Anatomica

Vol. 172, No. 3, Year 2002 (Cover Date: 2002)

Formerly Acta Anatomica

Journal Editor: H.-W. Denker, Essen; A.W. English, Atlanta, Ga.
ISSN: 1422–6405 (print), 1422–6421 (Online)

For additional information: http://www.karger.com/journals/cto


Article / Publication Details

First-Page Preview
Abstract of Paper

Received: 12/17/2001
Published online: 12/18/2002

Number of Print Pages: 13
Number of Figures: 10
Number of Tables: 1

ISSN: 1422-6405 (Print)
eISSN: 1422-6421 (Online)

For additional information: http://www.karger.com/CTO


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.